Literature DB >> 23364389

Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma.

Yohei Mano1, Shinichi Aishima, Nobuhiro Fujita, Yuki Tanaka, Yuichiro Kubo, Takashi Motomura, Akinobu Taketomi, Ken Shirabe, Yoshihiko Maehara, Yoshinao Oda.   

Abstract

OBJECTIVE: Signal transducer and activator of transcription 3 (STAT3) is activated in hepatocellular carcinoma (HCC), and tumor-associated macrophage plays an important role in tumor progression. Therefore, we examined STAT3 activation, cytokine expression and infiltration of tumor-associated macrophages in resected HCCs as well as the alteration of cell growth and migration by cytokine stimulation in HCC cell lines.
METHODS: Immunohistochemical staining of phosphorylated STAT3 (pSTAT3), CD163, interleukin (IL)-6, Ki-67 and Bcl-XL was performed for 101 cases of resected HCC, and correlations between pSTAT3 staining and clinicopathological findings were analyzed. In HCC cell lines (PLC/PRF/5 and Huh7), cell proliferation and migration by IL-6 stimulation and S3I-201 (STAT3 inhibitor) treatment were analyzed.
RESULTS: In HCC specimens, the pSTAT3-positive group showed high levels of α-fetoprotein (p = 0.0276), large tumor size (p = 0.0092), frequent intrahepatic metastasis (p = 0.0214), high Ki-67 (p = 0.0002) and Bcl-XL (p = 0.0001), poor prognosis (p = 0.0234), and high recurrence rate (p = 0.0003). CD163-positive cells were frequently observed in the pSTAT3-positive group (p = 0.0013). In two HCC cell lines, IL-6 stimulation promoted cell proliferation and migration via the STAT3 phosphorylation, and S3I-201 inhibited this activation.
CONCLUSIONS: STAT3 activation was correlated with aggressive behavior of HCC and may be mediated via tumor-associated macrophage. We expect that STAT3 signaling and tumor-associated macrophages can be attractive therapeutic targets in HCC patients.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23364389     DOI: 10.1159/000346196

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  45 in total

1.  Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma.

Authors:  Lin-Lin Bu; Wei-Wei Deng; Cong-Fa Huang; Bing Liu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection.

Authors:  Ze-Xiao Lin; Dan-Yun Ruan; Yang Li; Dong-Hao Wu; Xiao-Kun Ma; Jie Chen; Zhan-Hong Chen; Xing Li; Tian-Tian Wang; Qu Lin; Jing-Yun Wen; Xiang-Yuan Wu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

3.  Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.

Authors:  Yuichiroh Umemoto; Shinji Okano; Yoshihiro Matsumoto; Hidekazu Nakagawara; Rumi Matono; Shohei Yoshiya; Yo-Ichi Yamashita; Tomoharu Yoshizumi; Toru Ikegami; Yuji Soejima; Mamoru Harada; Shinichi Aishima; Yoshinao Oda; Ken Shirabe; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2014-02-08       Impact factor: 7.527

4.  Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.

Authors:  E Flashner-Abramson; S Klein; G Mullin; E Shoshan; R Song; A Shir; Y Langut; M Bar-Eli; H Reuveni; A Levitzki
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

5.  Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma.

Authors:  Carl Ludwig Behnes; Felix Bremmer; Bernhard Hemmerlein; Arne Strauss; Philipp Ströbel; Heinz-Joachim Radzun
Journal:  Virchows Arch       Date:  2013-12-11       Impact factor: 4.064

Review 6.  Cancer-associated fibroblasts in hepatocellular carcinoma.

Authors:  Norio Kubo; Kenichiro Araki; Hiroyuki Kuwano; Ken Shirabe
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

7.  STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.

Authors:  Weiyun Li; Jun Xiao; Xin Zhou; Ming Xu; Chaobo Hu; Xiaoyan Xu; Yao Lu; Chang Liu; Shengjie Xue; Lei Nie; Haibin Zhang; Zhiqi Li; Yanbo Zhang; Fu Ji; Lijian Hui; Wufan Tao; Bin Wei; Hongyan Wang
Journal:  J Clin Invest       Date:  2015-10-12       Impact factor: 14.808

8.  Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3.

Authors:  Qin Wang; Feng Cheng; Ting-Ting Ma; Hai-Yu Xiong; Zi-Wei Li; Chang-Li Xie; Cui-Ying Liu; Zhi-Guang Tu
Journal:  Mol Cell Biochem       Date:  2016-03-22       Impact factor: 3.396

9.  A Novel Systemic Inflammatory Score Combined With Immunoinflammatory Markers Accurately Reflects Prognosis in Patients With Esophageal Cancer.

Authors:  Takafumi Suzuki; Yusuke Ishibashi; Hironori Tsujimoto; Shinsuke Nomura; Keita Kouzu; Yujiro Itazaki; Takao Sugihara; Manabu Harada; Nozomi Ito; Hidekazu Sugasawa; Yoji Kishi; Hideki Ueno
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

10.  A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.

Authors:  Kaixin Du; Yulu Li; Juan Liu; Wei Chen; Zhizhong Wei; Yong Luo; Huisi Liu; Yonghe Qi; Fengchao Wang; Jianhua Sui
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.